RxDoctor Payments Data

Kelly Ocarroll, MD

Internal Medicine · Granbury, TXNPI 1669677159

Payments from drug & device makers

$2,872in general payments, 2019–2025

Across 131 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$673
  • Amgen$627
  • Lilly USA, LLC$337
  • Pfizer$179
  • Novo Nordisk$145
  • Takeda Pharmaceuticals U.S.A., Inc.$134
  • plus $776 from 24 others

What the payments were for

  • Food & beverage$2,84799%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,872 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,531
Medicare patients
161
Services billed
1,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$63,033
MounjaroTirzepatide34$33,871
JanuviaSitagliptin Phosphate23$28,841
OzempicSemaglutide13$20,780
XareltoRivaroxaban15$14,206
Combivent RespimatIpratropium/Albuterol Sulfate27$13,933
JardianceEmpagliflozin12$12,015
JanumetSitagliptin Phos/Metformin Hcl11$10,826
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,633
Rosuvastatin Calcium176$3,807
SynthroidLevothyroxine Sodium57$3,467
Colestipol Hcl31$2,989
Atorvastatin Calcium260$2,441
Metoprolol Succinate163$2,270
Fluticasone Propionate87$2,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$63,03354 claims
MerckJanuvia, Janumet$12$39,66734 claims
Lilly USA, LLCMounjaro$337$33,87134 claims
Novo NordiskOzempic$145$20,78013 claims
AbbVieSynthroid$673$3,46757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →